First JAK Inhibitor Approved by FDA for Treatment of Crohn's

[Scipio]

Rinvoq:

First JAK Inhibitor Approved for Crohn's Disease

Upadacitinib lands indication for moderately to severely active disease in adults

www.medpagetoday.com

A new class of drugs for Crohn's and thus new treatment options. Due to increased risk of blood clots and cancer, use of Rinvoq is to restricted those Crohn's patients who have already flunked therapy with anti-TNFs such as Remicade or Humira.

 

[Crohn2357]

This seems to be the most unsafe drug ever to get an approval for the treatment of CD.

I wouldn’t consider using jak inhibitors unless I really had no other choice.

 

[sashaz]

Im newly on Rinvoq, should I ask to change it?

 

[cyberviper]

I remember getting asked to join a trial for it, thankfully i refused

 

[kiny]

I remember getting asked to join a trial for it, thankfully i refused

Good for you. I hope people realize the danger of these drugs and their lack of effectiveness in crohn's disease. There is enormous financial pressure on companies due to anti-TNF patents expiring and cheaper biosimilar replacing them.

I warned multiple times about them:

Another JAK1 inhibitor fails clinical trials for crohn's disease.

Galapagos ADRs Down 7% as Crohn's Study Misses Endpoints. Galapagos NV American depositary receipts fell 7% to $40.45 in late trading after a Phase 3 trial of filgotinib for Crohn's disease didn't meet two co-primary endpoints. Galapagos said it decided not to submit a Marketing Authorization...

crohnsforum.com